Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R. Lopez-Cortes LF, et al. J Antimicrob Chemother. 2006 Nov;58(5):1017-23. doi: 10.1093/jac/dkl357. Epub 2006 Sep 6. J Antimicrob Chemother. 2006. PMID: 16956905 Clinical Trial.
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M. Marin-Niebla A, et al. Antimicrob Agents Chemother. 2007 Jun;51(6):2035-42. doi: 10.1128/AAC.01136-06. Epub 2007 Mar 19. Antimicrob Agents Chemother. 2007. PMID: 17371813 Free PMC article. Clinical Trial.
Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
López-Cortés LF, Ruiz-Valderas R, Viciana P, Mata R, Gómez-Vera J, Alarcón A, Pachón J. López-Cortés LF, et al. J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):240-2. doi: 10.1097/00126334-200302010-00019. J Acquir Immune Defic Syndr. 2003. PMID: 12571537 Clinical Trial. No abstract available.
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
Gutiérrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terrón A, Rivero A, López-Cortés LF; Sociedad Andaluza de Enfermedades Infecciosas. Gutiérrez-Valencia A, et al. Ann Intern Med. 2009 Aug 4;151(3):149-56. doi: 10.7326/0003-4819-151-3-200908040-00127. Epub 2009 Jul 6. Ann Intern Med. 2009. PMID: 19581631 Free article. Clinical Trial.
238 results